Zealand Pharma A/S (ZLDPF) vs. Its Rivals Head-To-Head Review

Zealand Pharma A/S (OTCMKTS:ZLDPF) is one of 844 public companies in the “Biotechnology” industry, but how does it weigh in compared to its rivals? We will compare Zealand Pharma A/S to related companies based on the strength of its dividends, valuation, risk, institutional ownership, analyst recommendations, profitability and earnings.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Zealand Pharma A/S and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zealand Pharma A/S	0	8	1	2	2.45
Zealand Pharma A/S Competitors	9847	15133	45510	1589	2.54

As a group, “Biotechnology” companies have a potential upside of 100.38%. Given Zealand Pharma A/S’s rivals stronger consensus rating and higher possible upside, analysts clearly believe Zealand Pharma A/S has less favorable growth aspects than its rivals.

Earnings & Valuation

This table compares Zealand Pharma A/S and its rivals gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Zealand Pharma A/S	$1.40 billion	$977.29 million	6.09
Zealand Pharma A/S Competitors	$698.13 million	$10.43 million	-15.31

Zealand Pharma A/S has higher revenue and earnings than its rivals. Zealand Pharma A/S is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Zealand Pharma A/S and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zealand Pharma A/S	58.86%	17.56%	16.17%
Zealand Pharma A/S Competitors	-12,359.35%	-203.09%	-30.93%

Volatility and Risk

Zealand Pharma A/S has a beta of 0.99, suggesting that its stock price is 1% less volatile than the S&P 500. Comparatively, Zealand Pharma A/S’s rivals have a beta of 1.14, suggesting that their average stock price is 14% more volatile than the S&P 500.

Insider and Institutional Ownership

47.9% of shares of all “Biotechnology” companies are owned by institutional investors. 13.0% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Zealand Pharma A/S beats its rivals on 7 of the 13 factors compared.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.